Hot Flashes, Big News – Nurses, Your Voice on Menopause Matters
The U.S. Food & Drug Administration (FDA) has approved Lynkuet (elinzanetant), the first dual neurokinin-1/3 (NK1/NK3) receptor antagonist, as a hormone-free treatment for moderate-to-severe hot flashes and night sweats due to menopause.
This milestone marks a major advancement in women’s health and is a timely reminder that nurses, especially women clinicians, must be at the forefront of telling these stories
Interested in learning how you can use media to amplify your voice?
Check out our latest newsletter to learn more. https://wix.to/MoE6uh0
2026 MediaRX Academy starts April 6, 2026.
Learn more ➡️ https://www.themediarx.com/academy
2 Views
